![logo](/logos/IHL.AX.webp)
Incannex Healthcare Limited
ASX:IHL.AX
0.04 (AUD) • At close November 21, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Incannex Healthcare Limited |
Symbool | IHL.AX |
Munteenheid | AUD |
Prijs | 0.041 |
Beurswaarde | 65,067,410 |
Dividendpercentage | 0% |
52-weken bereik | 0.041 - 0.28 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Joel Bradley Latham |
Website | https://www.incannex.com.au |
An error occurred while fetching data.
Over Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)